WIN-IND: Intas Semaglutide Trial

WIN-IND compared an Intas Pharmaceuticals version of semaglutide with Novo Nordisk's reference product in Indian adults whose type 2 diabetes remained inadequately controlled on metformin. After 24 weeks, average HbA1c fell by a similar amount in both groups, and the paper calls the Intas product non-inferior^[1]. That conclusion needs a closer read: the reported 95% confidence interval extends to 0.47 percentage points, beyond the stated 0.4-point margin, while the paper applies the margin to the opposite end of the interval. The efficacy results look close, but the published non-inferiority calculation needs clarification before it is treated as settled.

What WIN-IND tested

WIN-IND was a phase 3, randomised, open-label, active-controlled trial of semaglutide at 29 sites across India. The registry lists Intas Pharmaceuticals as the sponsor and a target sample of 250. Recruitment began on 2 July 2025, and the record now marks the study completed^[3]. The paper reports 223 people in the safety set, meaning everyone who received at least one dose, and 217 in the intention-to-treat efficacy set, meaning treated participants with at least one efficacy assessment^[1].

Participants were 18 to 65 years old, had an HbA1c from 7% to below 10.5%, and had been using metformin alongside diet and exercise. They were randomised 1:1 to Intas semaglutide or the reference semaglutide for 24 weeks. The protocol used the same glucose-guided escalation schedule in both arms, from 0.25 mg weekly to as much as 2 mg weekly. This describes the trial design, not a dosing recommendation^[1][3]. Our semaglutide overview separates research schedules from individual treatment decisions.

The HbA1c result

Baseline HbA1c averaged 8.4% in each arm. At week 24, the least-squares mean change was -1.50 percentage points with Intas semaglutide and -1.65 with the reference product. The reported test-minus-reference difference was 0.16 points (95% CI -0.16 to 0.47; P=0.3266). The per-protocol analysis, limited to 205 participants, was similar at 0.15 points (95% CI -0.16 to 0.46)^[1].

Other measured changes with semaglutide were also close. Mean fasting glucose fell by 21.9 mg/dL with the test product and 22.5 mg/dL with the reference. Post-meal glucose fell by 37.4 and 36.5 mg/dL, while body weight fell by 6.0 and 5.8 kg, respectively. None of those between-group comparisons was statistically significant^[1]. Those figures support similarity over this 24-week window. They do not, on their own, prove that the products are interchangeable in every clinical setting.

Why the non-inferiority claim needs clarification

A non-inferiority trial does not try to show two products are identical. It asks whether the test product is no worse than the reference by more than a prespecified margin. WIN-IND set that margin at 0.4 HbA1c percentage points. Because a larger HbA1c reduction is better and the reported contrast is test minus reference, the concerning direction is a positive difference. Under the usual framing, the upper confidence limit would need to stay below +0.4.

The paper instead says non-inferiority was confirmed because the lower limit, -0.16, was above -0.4, even though the upper limit was 0.47^[1]. As printed, the contrast, the direction of benefit and the decision rule do not line up. This could be a reporting or sign-convention error, but no public protocol or statistical analysis plan was available in the sources we reviewed to resolve it. The safest reading is that the observed means were close, while the formal non-inferiority conclusion requires author or peer-review clarification.

Safety and immunogenicity

In the safety set, 61 of 112 people (54.5%) receiving Intas semaglutide and 43 of 111 (38.7%) receiving the reference reported at least one treatment-emergent adverse event. Gastrointestinal events were common in both groups. The paper reports no deaths, serious adverse events or treatment discontinuations due to adverse events, and says no new safety signal was identified^[1][2]. The overall event count was higher in the test arm, so "similar" should not be read as numerically identical. Our semaglutide safety summary covers the established adverse-event context.

Confirmatory anti-drug antibodies to semaglutide remained uncommon, at no more than 3.6% in either group after dosing. Neutralising antibodies were also infrequent, reaching a maximum of 2.7% with the test product and 0.9% with the reference. The investigators reported no observed effect on efficacy or safety during the study^[1]. A 24-week trial with 223 treated participants cannot exclude uncommon immune or safety problems.

Sponsor involvement and conflicts

Intas Pharmaceuticals funded the semaglutide trial. Five authors were Intas employees, several of whom reported roles in funding acquisition, methods and drafting the manuscript. The acknowledgements also credit an Intas employee for medical writing assistance^[1]. Industry sponsorship does not invalidate a trial, but it makes transparent methods and an unambiguous primary analysis especially important. The paper's suggestion that the product may be cost-effective is not supported by a pharmacoeconomic analysis, a limitation the authors acknowledge.

What we do not know yet

WIN-IND does not answer whether the two semaglutide products perform similarly beyond 24 weeks, in adults older than 65, outside India or in people using different background therapies. It was open-label, and missing primary-endpoint data were filled using last observation carried forward, a method that can preserve older measurements after a participant drops out^[1]. The full dataset is not public because the paper cites institutional restrictions.

We also do not have a public analysis plan that explains the direction of the non-inferiority rule. That document, plus independent replication and longer follow-up, would make the comparison easier to judge. Nothing in this readout changes semaglutide's prescription status or supports switching products without clinical guidance. See the semaglutide evidence page and its regulatory overview for broader context.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.